CYCC vs. TLPH, INDP, CDT, ENSC, MYNZ, SPRC, BFRI, CYCN, EGRX, and AIMD
Should you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Talphera (TLPH), Indaptus Therapeutics (INDP), Conduit Pharmaceuticals (CDT), Ensysce Biosciences (ENSC), Mainz Biomed (MYNZ), SciSparc (SPRC), Biofrontera (BFRI), Cyclerion Therapeutics (CYCN), Eagle Pharmaceuticals (EGRX), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry.
Cyclacel Pharmaceuticals vs.
Talphera (NASDAQ:TLPH) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment, earnings and community ranking.
Talphera has a beta of 0.28, suggesting that its share price is 72% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500.
Talphera has a net margin of 0.00% compared to Cyclacel Pharmaceuticals' net margin of -18,150.00%. Talphera's return on equity of -118.46% beat Cyclacel Pharmaceuticals' return on equity.
Talphera currently has a consensus target price of $4.50, suggesting a potential upside of 614.06%. Cyclacel Pharmaceuticals has a consensus target price of $11.00, suggesting a potential upside of 2,955.56%. Given Cyclacel Pharmaceuticals' higher probable upside, analysts plainly believe Cyclacel Pharmaceuticals is more favorable than Talphera.
37.7% of Talphera shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 3.2% of Talphera shares are owned by company insiders. Comparatively, 8.0% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Talphera had 2 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 3 mentions for Talphera and 1 mentions for Cyclacel Pharmaceuticals. Talphera's average media sentiment score of 0.26 beat Cyclacel Pharmaceuticals' score of -0.17 indicating that Talphera is being referred to more favorably in the media.
Talphera has higher revenue and earnings than Cyclacel Pharmaceuticals. Talphera is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Cyclacel Pharmaceuticals received 180 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 46.40% of users gave Cyclacel Pharmaceuticals an outperform vote.
Summary
Talphera beats Cyclacel Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Cyclacel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclacel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CYCC) was last updated on 1/22/2025 by MarketBeat.com Staff
